Introduction {#s0005}
============

Osteoporosis is characterized by low bone mineral density (BMD) and deterioration in bone microarchitecture which results in fragility and increased risk for fracture [@bb0005]. Several large genome-wide association studies (GWAS) have recently identified single nucleotide polymorphisms (SNPs) associated with BMD and fracture risk [@bb0010; @bb0015]. However combinations of these SNPs only contribute approximately 5% of the risk of developing osteoporosis [@bb0020]. Alternative structural genomic mechanisms, including copy number variations (CNVs), are being investigated as a source of phenotypic variation in diseases such as asthma, autoimmune disease and psychiatric disease [@bb0025; @bb0030; @bb0035; @bb0040; @bb0045; @bb0050; @bb0055; @bb0060; @bb0065] and recent data suggests CNVs may also be relevant to osteoporosis [@bb0020; @bb0070].

In 2009, Yerges et al. screened for associations between SNPs in 383 candidate genes and femoral neck and lumbar spine volumetric BMD and found three SNPs in the *APC* gene to be strongly associated [@bb0075]. In addition, Miclea et al. conducted a cross-sectional study and reported familial adenomatous polyposis (FAP) patients with heterozygous mutations within the *APC* gene displayed significantly higher mean BMD than age- and sex‐matched controls [@bb0080]. The *APC* tumor suppressor gene encodes for a protein known to be involved in a broad spectrum of cellular processes including apoptosis, adhesion, cell cycle control, cell migration and chromosomal stability [@bb0085; @bb0090; @bb0095]. However, its main role is to bind β-catenin, a key transducer of the Wnt signaling pathway, and negatively regulate the Wnt signaling cascade [@bb0100; @bb0105]. There is emerging evidence of the important role of β-catenin in bone regulation and the pathophysiology of skeletal disorders [@bb0110; @bb0115; @bb0120]. Interestingly, mice carrying a heterozygous loss of function mutation in *Apc* display significantly increased BMD of the distal femur [@bb0125]. Collectively, these data strongly imply that *APC* may have a role in BMD through β-catenin regulation. In this study, we performed a candidate gene study of *APC* CNV to further examine the effect of genetic variation in the *APC* gene on BMD.

Material and methods {#s0010}
====================

Subjects and clinical assessment {#s0030}
--------------------------------

Subjects who participate in the study were identified from the St Thomas\' UK adult twin registry (TwinsUK) and included both males and females between 16 and 81 years of age. Measurement of the anterior--posterior projection of forearm, lumbar spine (L1--4) and total hip BMD was performed using DEXA (QDR 4500, Hologic) as described previously [@bb0130]. Clinical data which included age, height and weight were collected at interview and lifestyle questionnaires were also completed. Body mass index (BMI) was derived by computation: weight (kg)/height (m)^2^. All subjects from the TwinsUK cohort provided written informed consent, and the institutional ethics committees of participating institutions approved the experiment protocols.

Genotyping and CNV calling {#s0035}
--------------------------

Genotyping was performed on genomic DNA extracted from venous blood and analyzed using the Human Hap610 Quad array (Illumina, San Diego, USA) according to the manufacturer\'s instructions. PennCNV software was used for the calling of CNVs, which uses the combined values of log R ratio and B allele frequency values and an integrated hidden Markov model [@bb0135]. Quality control threshold was performed as per PennCNV guidelines [@bb0135].

Linkage disequilibrium {#s0040}
----------------------

To assess the linkage disequilibrium of the *APC* CNV with surrounding SNPs using available software, we recoded the CNV call as a bi-allelic variable ("one copy loss" = TA and "two copy" = TT) and combined this with the SNP genotype data obtained from the Human Hap610 Quad array. We used SNP genotype data from all SNPs in the gene region including approximately 45 kb before and after the *APC* gene, and perform linkage disequilibrium analysis using Haploview 4.2 [@bb0140].

Statistical analyses {#s0045}
--------------------

Statistical analysis was performed using SPSS for Windows v17.0 (SPSS Inc., Chicago, IL, USA). All individuals in the study were from independent families with only a single sib from each pedigree participating in the study. We first tested whether the following variables: age, age^2^, height, BMI and sex were significantly associated with BMD phenotypes using multiple linear regression --- all variables were retained as covariates in subsequent analyses. BMD standardized residuals were generated after adjustment for covariates and the differences in mean BMD for each genotype group were examined using independent t-test. Two-tailed *P* values are reported throughout, with values ≤ 0.05 considered statistically significant.

Results {#s0015}
=======

The demographic data and bone density parameters for the study subjects are detailed in [Table 1](#t0005){ref-type="table"}.

Among the 2070 participants, eight subjects (0.4%) had a heterozygous deletion encompassing a portion of the *APC* gene, with the remaining 2062 (99.6%) subjects having two copies of the *APC* gene. No subjects were detected with homozygous deletion or copy gain in this region. Out of the eight subjects with a single copy deletion, there were seven females and one male individual. Interestingly, the eight different heterozygous deletions of the *APC* gene share a common deletion region (chr5:112144628--112152268 (hg18)), clustered near the 3′ end of exon 5 of the *APC* gene ([Fig. 1](#f0005){ref-type="fig"}). However it is unclear whether a specific region within the CNV is responsible for the effect on BMD or whether any of the observed combination of deletions of exons is sufficient to elicit the effect. In support of the PennCNV genotypes for this region, a distinct decrease in log R ratio values for the eight single copy subjects encompassing only the *APC* gene, compared to 100 kb before and after the gene, was evident on examination of the genotyping array data ([Fig. 2](#f0010){ref-type="fig"}).

The pairwise linkage disequilibrium (*r*^2^) of SNPs in the region approximately 45 kb before and after the *APC* gene (chr5:112055101--112254554 (hg18)) and the *APC* CNV is depicted in [Fig. 3](#f0015){ref-type="fig"}. This analysis showed that the common one-copy deletion region, shared by the eight affected subjects, is not in strong linkage disequilibrium with any of the surrounding SNPs.

There was evidence of significant association between *APC* CNV genotype and BMD at all sites studied: forearm, spine and total hip (*P* = 0.023, *P* = 0.004 and *P* = 0.002 respectively; [Table 2](#t0010){ref-type="table"}) after adjustment for age, age^2^, height, BMI and sex. Subjects with heterozygous deletion of the *APC* gene showed 7.95%, 13.10% and 13.36% higher mean forearm, spine and total hip sites respectively compared to subjects with two copies of the *APC* gene.

Discussion {#s0020}
==========

The data presented in this study provides evidence that CNV within the *APC* gene is associated with increased BMD in a Caucasian cohort of 2070 individuals. We found strong evidence that subjects with single copy loss of *APC* display a significantly higher mean BMD than subjects with two copies of *APC*. These finding suggest that the *APC* gene may be an important negative regulator of bone mineral density in humans. Our results are in agreement with a recently published study reporting that FAP patients with heterozygous mutation in the *APC* gene also displayed increased mean BMD [@bb0080]. In addition, our findings in humans are supported by the study of Holmen et al. which demonstrated that mice with osteoblast-specific deletion of the *Apc* gene revealed significant accumulation of bone matrix in the femur and dramatically increased bone deposition associated with disturbances in bone architecture and composition in the tibia [@bb0125].

A proportion of CNVs in the genome are in strong linkage disequilibrium with common SNPs and potential association of those CNVs can be assessed by association testing with the SNPs acting as surrogate markers. However this is not the case for all CNVs and in this study we have shown that the CNV in the *APC* gene is not in strong linkage disequilibrium with any of the surrounding SNPs. This lack of linkage disequilibrium may account for the *APC* gene not being documented to be associated with the regulation of BMD in recent GWAS. In addition to identifying a novel CNV association with BMD, our study also shows the importance of direct analysis of CNVs and their role in diseases as it is not always possible to draw appropriate conclusions from tagSNP studies alone.

We and others have previously examined the role of candidate CNVs in osteoporosis and regulation of BMD [@bb0020; @bb0070; @bb0145] and this study further adds to the growing body of literature on the role of CNVs in bone metabolism. Our findings on the effect of *APC* CNV on BMD compliment and extend the findings of Yerges et al. [@bb0075]. Data from studies of human missense mutations and that from the conditional knockout mouse are similarly in accord with the findings of our research. However, this is the first study that examined the effects of CNV within the *APC* gene in BMD regulation in humans.

The tumor suppressor *APC* is an intracellular cytosolic Wnt signaling inhibitor which forms a 'multi-protein destruction complex' with axin and glycogen synthase kinase 3 (GSK3) [@bb0150]. Together with axin, *APC* acts as a scaffold protein, increasing the affinity of GSK3 to bind and phosphorylate β-catenin, leading to its degradation by the β-TrCP-mediated ubiquitination/proteasome pathway [@bb0155]. This results in the deactivation of the canonical Wnt signaling pathway. However, loss of *APC* disrupts the destruction complex, thereby preventing the phosphorylation and degradation of β-catenin, leading to its cytoplasmic stabilization and proliferation [@bb0160]. In the murine models presented by Holmen et al., mice carrying osteoblast-specific deletions of both *Apc* and the β-catenin genes are phenotypically similar to those lacking only the β-catenin gene. This confirms that the phenotype induced by loss of *Apc* is due to dysregulation of β-catenin signaling [@bb0125].

The most common target for both germ line and somatic mutation within the *APC* gene lies mainly in exon 15, where more than 75% of the coding sequence is located [@bb0165; @bb0170]. In our study, only one affected individual had a single copy deletion encompassing all exons, including exon 15, however the phenotype of that individual was not significantly different in comparison to other individuals with a 1 copy loss. Although the common deletion region that the eight affected individuals share is located within intron 6, this region does cover regulatory elements, including enhancer elements [@bb0175]. In addition, the single copy loss for every individual encompasses at least 4 exons, which suggests that each deletion would result in an abnormal or non-functional APC protein. As there is strong evidence of the pivotal role of Wnt signaling in bone regulation, this would imply that haploinsufficiency of *APC* results in over-activation of the canonical Wnt signaling pathway via the stabilization of more β-catenin, increasing bone mass through diverse range of mechanisms such as osteoblastogenesis induction, apoptosis inhibition of osteoblast and osteocyte, stimulation of preosteoblast replication and the renewal of stem cells [@bb0180; @bb0185; @bb0190; @bb0195].

Conclusions {#s0025}
===========

Our data add to the accumulating evidence regarding the importance of CNV in the regulation of BMD and the role of the *APC* gene as an antagonist to the canonical Wnt signaling pathway in the regulation of bone mass. This study also demonstrates that as for some other complex genetic diseases, CNVs may play a role in the regulation of key clinically relevant traits and that this effect is not always defined by attempting to exploit linkage disequilibrium of CNVs with common tagSNPs.
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![Location of the *APC* gene copy number variations in the eight individuals from the TwinsUK cohort. The *APC* gene transcript spans 108 kb at chromosome 5q22.2 (NCBI Genome Build 36/hg18).](gr1){#f0005}

![Graph of log R ratio by chromosomal position for the eight subjects with a single copy loss of the *APC* CNV in the *APC* gene region. Gray symbols represent log R ratio for SNPs upstream/downstream of the CNV region and gray lines represent expected value for two copies. Black symbols represent log R ratio for SNPs within the CNV region and the black line indicates the expected value of a loss in copy number (NCBI Genome Build 36/hg18).](gr2){#f0010}

![Linkage disequilibrium plot of the *APC* gene region for the TwinsUK cohort. The region of one copy loss shared among the eight affected individuals is titled APC CNV. Pairwise linkage disequilibrium, measured as *r*^2^, was calculated from genotyping data using Haploview 4.2.](gr3){#f0015}

###### 

Demographic data and bone density parameters of the TwinsUK cohort.

  ---------------------------------------------------------
  Variables                 Females\        Males\
                            (n = 1815)      (n = 255)
  ------------------------- --------------- ---------------
  Age (years)               46.8 ± 12.8     48.3 ± 14.0

  Height (m)                1.62 ± 0.07     1.75 ± 0.07

  Weight (kg)               67.0 ± 12.6     80.7 ± 12.4

  BMI (kg/m^2^)             25.5 ± 6.7      26.3 ± 3.9

  Forearm BMD (g/cm^2^)     0.555 ± 0.058   0.658 ± 0.062

  Spine BMD (g/cm^2^)       0.997 ± 0.142   1.026 ± 0.151

  Total hip BMD (g/cm^2^)   0.930 ± 0.129   1.042 ± 0.144
  ---------------------------------------------------------

Data are mean ± SD.

###### 

Mean bone mineral density parameters by body site in relation to the *APC* CNV genotype.

  Variable                  1 copy          2 copies        *P* value
  ------------------------- --------------- --------------- -----------
  Forearm BMD (g/cm^2^)     0.607 ± 0.018   0.566 ± 0.001   0.023
  Spine BMD(g/cm^2^)        1.137 ± 0.047   1.000 ± 0.003   0.004
  Total hip BMD (g/cm^2^)   1.077 ± 0.042   0.943 ± 0.003   0.002

Results are given as mean ± SEM. *P*-values were determined using independent t-test after adjustment for age, age^2^, height, BMI and sex.
